The future of atrial fibrillation therapy: intervention on heat shock proteins influencing electropathology is the next in line
Tóm tắt
Atrial fibrillation (AF) is the most common age-related cardiac arrhythmia accounting for one-third of hospitalisations. Treatment of AF is difficult, which is rooted in the progressive nature of electrical and structural remodelling, called electropathology, which makes the atria more vulnerable for AF. Importantly, structural damage of the myocardium is already present when AF is diagnosed for the first time. Currently, no effective therapy is known that can resolve this damage. Previously, we observed that exhaustion of cardioprotective heat shock proteins (HSPs) contributes to structural damage in AF patients. Also, boosting of HSPs, by the heat shock factor-1 activator geranylgeranylacetone, halted AF initiation and progression in experimental cardiomyocyte and dog models for AF. However, it is still unclear whether induction of HSPs also prolongs the arrhythmia-free interval after, for example, cardioversion of AF. In this review, we discuss the role of HSPs in the pathophysiology of AF and give an outline of the HALT&REVERSE project, initiated by the HALT&REVERSE Consortium and the AF Innovation Platform. This project will elucidate whether HSPs (1) reverse cardiomyocyte electropathology and thereby halt AF initiation and progression and (2) represent novel biomarkers that predict the outcome of AF conversion and/or occurrence of post-surgery AF.
Tài liệu tham khảo
Dobrev D, Carlsson L, Nattel S. Novel molecular targets for atrial fibrillation therapy. Nat Rev Drug Discov. 2012;11:275–91.
Wijffels MC, Kirchhof CJ, Dorland R, Allessie MA. Atrial fibrillation begets atrial fibrillation. A study in awake chronically instrumented goats. Circulation. 1995;92:1954–68.
Ausma J, Wijffels M, Thone F, Wouters L, Allessie M, Borgers M. Structural changes of atrial myocardium due to sustained atrial fibrillation in the goat. Circulation. 1997;96:3157–63.
Brundel BJJM, Ausma J, Gelder IC Van, et al. Activation of proteolysis by calpains and structural changes in human paroxysmal and persistent atrial fibrillation. Cardiovasc Res. 2002;54:380–9.
Groot N De, Houden R, Smeets J, et al. Electropathological substrate of longstanding persistent atrial fibrillation in patients with structural heart disease: epicardial breakthrough. Circulation. 2010;122:1674–82.
Allessie M, Ausma J, Schotten U. Electrical, contractile and structural remodeling during atrial fibrillation. Cardiovasc Res. 2002;54:230–46.
Spach MS, Heidlage JF, Dolber PC, Barr RC. Electrophysiological effects of remodeling cardiac gap junctions and cell size: experimental and model studies of normal cardiac growth. Circ Res. 2000;86:302–11.
Spach MS, Dolber PC. Relating extracellular potentials and their derivatives to anisotropic propagation at a microscopic level in human cardiac muscle. Evidence for electrical uncoupling of side-to-side fiber connections with increasing age. Circ Res. 1986;58:356–71.
Velden HM van der, Ausma J, Rook MB, et al. Gap junctional remodeling in relation to stabilization of atrial fibrillation in the goat. Cardiovasc Res. 2000;46:476–86.
Velden HMW Van der, Kempen MJA Van, Wijffels M, et al. Altered pattern of connexin40 distribution in persistent atrial fibrillation in the goat. J Cardiovasc Electrophysiol. 1998;9:596–607.
Koura T, Hara M, Takeuchi S, et al. Anisotropic conduction properties in canine atria analyzed by high-resolution optical mapping: preferential direction of conduction block changes from longitudinal to transverse with increasing age. Circulation. 2002;105:2092–8.
Brundel BJJM, Gelder IC Van, Henning RH, et al. Ion channel remodeling is related to intra-operative atrial refractory periods in patients with paroxysmal and persistent atrial fibrillation. Circulation. 2001;103:684–90.
Ke L, Qi XY, Dijkhuis AJ, et al. Calpain mediates cardiac troponin degradation and contractile dysfunction in atrial fibrillation. J Mol Cell Cardiol. 2008;45:685–93.
Spach MS. Anisotropy of cardiac tissue: a major determinant of conduction? J Cardiovasc Electrophysiol. 1999;10:887–90.
Konings KT, Smeets JL, Penn OC, Wellens HJ, Allessie MA. Configuration of unipolar atrial electrograms during electrically induced atrial fibrillation in humans. Circulation. 1997;95:1231–41.
Yaksh A, Kik C, Knops P, et al. Atrial fibrillation: to map or not to map? Neth Heart J. 2014;22:259–66.
Nademanee K. Trials and travails of electrogram-guided ablation of chronic atrial fibrillation. Circulation. 2007;115(20):2592–4.
Willis MS, Patterson C. Proteotoxicity and cardiac dysfunction. N Engl J Med. 2013;368:1755.
Brundel BJJM, Ke L, Dijkhuis AJ, et al. Heat shock proteins as molecular targets for intervention in atrial fibrillation. Cardiovasc Res. 2008;78:422–8.
Brundel BJJM, Henning RH, Ke L, Gelder IC Van, Crijns HJGM, Kampinga HH. Heat shock protein upregulation protects against pacing-induced myolysis in HL-1 atrial myocytes and in human atrial fibrillation. J Mol Cell Cardiol. 2006;41:555–62.
Chung J, Nguyen AK, Henstridge DC, et al. HSP72 protects against obesity-induced insulin resistance. Proc Natl Acad Sci U S A. 2008;105:1739–44.
Sakabe M, Shiroshita-Takeshita A, Maguy A, et al. Effects of heat shock protein induction on atrial fibrillation caused by acute atrial ischemia. Cardiovasc Res. 2008;78:63–70.
Chang SL, Chen YC, Hsu CP, et al. Heat shock protein inducer modifies arrhythmogenic substrate and inhibits atrial fibrillation in the failing heart. Int J Cardiol. 2013;168:4019–26.
Mandal K, Torsney E, Poloniecki J, Camm AJ, Xu Q, Jahangiri M. Association of high intracellular, but not serum, heat shock protein 70 with postoperative atrial fibrillation. Ann Thorac Surg. 2005;79:865–71.
St Rammos K, Koullias GJ, Hassan MO, et al. Low preoperative HSP70 atrial myocardial levels correlate significantly with high incidence of postoperative atrial fibrillation after cardiac surgery. Cardiovasc Surg. 2002;10:228–32.
Hu YF, Yeh HI, Tsao HM, et al. Electrophysiological correlation and prognostic impact of heat shock protein 27 in atrial fibrillation. Circ Arrhythm Electrophysiol. 2012;5:334–40.
Wakisaka O, Takahashi N, Shinohara T, et al. Hyperthermia treatment prevents angiotensin II-mediated atrial fibrosis and fibrillation via induction of heat-shock protein 72. J Mol Cell Cardiol. 2007;436:616–26.
Brundel BJJM, Shiroshita-Takeshita A, Qi XY, et al. Induction of heat-shock response protects the heart against atrial fibrillation. Circ Res. 2006;99:1394–402.
Ke L, Meijering RAM, Hoogstra-Berends F, et al. HSPB1, HSPB6, HSPB7 and HSPB8 protect against RhoA GTPase-induced remodeling in tachypaced HL-1 atrial myocytes. PloS One. 2011;6:e20395.
Zhang D, Ke L, Mackovicova K, et al. Effects of different small HSPB members on contractile dysfunction and structural changes in a Drosophila melanogaster model for atrial fibrillation. J Mol Cell Cardiol. 2011;51:381–9.
Yang M, Tan H, Cheng L, et al. Expression of heat shock proteins in myocardium of patients with atrial fibrillation. Cell Stress Chaperones. 2007;12:142–50.
Cao H, Xue L, Xu X, et al. Heat shock proteins in stabilization of spontaneously restored sinus rhythm in permanent atrial fibrillation patients after mitral valve surgery. Cell Stress Chaperones. 2011;16:517–28
Ooie T, Takahashi N, Saikawa T, et al. Single oral dose of geranylgeranylacetone induces heat-shock protein 72 and renders protection against ischemia/reperfusion injury in rat heart. Circulation. 2001;104:1837–43.
Katsuno M, Sang C, Adachi H, et al. Pharmacological induction of heat-shock proteins alleviates polyglutamine-mediated motor neuron disease. Proc Natl Acad Sci U S A. 2005;102:16801–6.